Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)

Technology appraisal
Reference number: TA848
Published: 01 December 2022

History

Invitation to participate

Final scope (PDF 245 KB)

Published:

23 April 2021
Final stakeholder list (PDF 159 KB)

Published:

23 April 2021
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 187 KB)

Published:

23 April 2021
Equality impact assessment (Scoping) (PDF 120 KB)

Published:

23 April 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 271 KB)

Published:

01 February 2021
Draft matrix post referral (PDF 158 KB)

Published:

01 February 2021